Synapse - Marc Ladanyi

Results (26)

HER2 antibody-drug conjugates are active against desmoplastic small round cell tumor

Journal Article

Zhang, T.; Febres-Aldana, C. A.; Liu, Z.; Dix, J. M.; Cheng, R.; Dematteo, R. G.; Lui, A. J. W.; Khodos, I.; Gili, L.; Mattar, M. S.; more...
Clinical Cancer Research (2024)

Fulltext@MSK | Save

Combination of MDM2 and targeted kinase inhibitors results in prolonged tumor control in lung adenocarcinomas with oncogenic tyrosine kinase drivers and MDM2 amplification

Journal Article

Elkrief, A.; Odintsov, I.; Smith, R. S.; Vojnic, M.; Hayashi, T.; Khodos, I.; Markov, V.; Liu, Z.; Lui, A. J. W.; Bloom, J. L.; more...
JCO Precision Oncology (2024)

Fulltext@MSK | Save

Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

Journal Article

Miyazaki, I.; Odintsov, I.; Ishida, K.; Lui, A. J. W.; Kato, M.; Suzuki, T.; Zhang, T.; Wakayama, K.; Kurth, R. I.; Cheng, R.; more...
Nature Cancer (2023)

Fulltext@MSK | Save

Prospective clinical genomic profiling of Ewing sarcoma: ERF and FGFR1 mutations as recurrent secondary alterations of potential biologic and therapeutic relevance

Journal Article

Ogura, K.; Elkrief, A.; Bowman, A. S.; Koche, R. P.; de Stanchina, E.; Benayed, R.; Mauguen, A.; Mattar, M. S.; Khodos, I.; Meyers, P. A.; more...
JCO Precision Oncology (2022)

Fulltext@MSK | Save

Tractable patient-derived models for preclinical therapeutic studies of CNS metastases

Meeting Abstract

Vojnic, M.; Odintsov, I.; Offin, M. D.; Lui, A. J. W.; Khodos, I.; Chang, Q.; Mattar, M. S.; De Stanchina, E.; Ladanyi, M.; Somwar, R.
Neuro-Oncology (2022)

Fulltext@MSK | Save

Comparison of TAS0953/HM06 and selpercatinib in RET fusion-driven preclinical disease models of intracranial metastases

Meeting Abstract

Odintsov, I.; Lui, A. J. W.; Ishizawa, K.; Miyazaki, I.; Khodos, I.; Wakayama, K.; Vojnic, M.; Hagen, C. J.; Chang, Q.; Bonifacio, A.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Vepafestinib is effective in preclinical models of sarcomas with RET fusion including a brain metastasis model

Meeting Abstract

Odintsov, I.; Liu, A.; Khodos, I.; Chang, Q.; Giuliano, C.; Mattar, M.; Vojnic, M.; Bonifacio, A.; De Stanchina, E.; Lovati, E.; more...
European Journal of Cancer (2022)

Fulltext@MSK | Save

TA0953/HM06, a novel RET-specific inhibitor effective in extracranial and CNS disease models of NSCLC with RETfusions

Meeting Abstract

Odintsov, I.; Lui, A. J. W.; Delasos, L.; Khodos, I.; Chang, Q.; Mattar, M. S.; Vojnic, M.; Lu, Y. C.; Kunte, S.; Bonifacio, A.; more...
Journal of Thoracic Oncology (2022)

Fulltext@MSK | Save

Targeting mTOR and MEK or ERK inhibits the growth of PDX models of NF1-deficient pediatric sarcoma

Meeting Abstract

Lu, Y. C.; Odintsov, I.; Khodos, I.; Mattar, M.; Glade Bender, J.; Wexler, L.; de Stanchina, E.; Ladanyi, M.; Somwar, R.
Pediatric Blood and Cancer (2022)

Fulltext@MSK | Save

Zenocutuzumab, a HER2XHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements

Journal Article

Schram, A. M.; Odintsov, I.; Espinosa-Cotton, M.; Khodos, I.; Sisso, W. J.; Mattar, M. S.; Lui, A. J. W.; Vojnic, M.; Shameem, S. H.; Chauhan, T.; more...
Cancer Discovery (2022)

Fulltext@MSK | Save